Ipamorelin + CJC-1295: The Growth Hormone Peptide Stack Redefining Body Composition After 40

Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.

After 40, your pituitary gland quietly starts dialing back growth hormone output. Not dramatically — just a steady 1–2% drop per year, compounding decade after decade until the cumulative effect shows up as softer midsections, slower recovery, disrupted sleep, and a body that seems to work against every effort you make in the gym or the kitchen. Sound familiar?

Here’s what most people don’t know: the pituitary isn’t broken. It still knows how to produce GH. It just needs a better signal. That’s the entire premise behind the Ipamorelin + CJC-1295 stack — two peptides that work on different receptor systems to amplify and restore the body’s own growth hormone pulse rather than replacing it from outside.

This guide covers everything you need to understand about how these two peptides work individually, why they’re dramatically more effective when combined, and what the research actually says about body composition, fat loss, muscle preservation, sleep, and anti-aging outcomes in adults.

What Is Ipamorelin and How Does It Work?

Ipamorelin is a growth hormone releasing peptide (GHRP) — specifically, a selective ghrelin receptor agonist. In a 2003 study published in the Journal of Clinical Endocrinology & Metabolism, synthetic GHRPs like ipamorelin produced a robust, dose-dependent GH pulse without the significant cortisol or prolactin elevation seen with earlier GHRPs like GHRP-6 and GHRP-2. That selectivity is a big deal clinically: cleaner GH pulses with far fewer unwanted hormonal side effects.

How does it actually work? Ipamorelin mimics ghrelin — the “hunger signal” peptide — at the pituitary’s ghrelin receptor (GHSR-1a). When it binds, the pituitary rapidly fires a burst of GH into circulation. The pulse is sharp and short, mimicking the natural episodic pattern your pituitary produced in your 20s. It does NOT produce continuous, flat-line GH elevations, which is why receptor downregulation and side effects are minimal.

Dr. Nguyen’s Clinical Perspective: In my experience with GH peptide protocols, ipamorelin is the GHRP I reach for first precisely because of its selectivity. Patients don’t get the hunger surges or cortisol spikes we saw historically with GHRP-6. The GH pulse is clean, the half-life is short (about 2 hours), and the receptor doesn’t habituate rapidly. For patients over 45 who are weight-loss resistant despite good diet and training habits, that clean nocturnal pulse is often the metabolic unlock they’ve been missing.

[INTERNAL-LINK: what is ipamorelin → dedicated ipamorelin overview article on TFW]

What Is CJC-1295 with DAC and Why Does the DAC Version Matter?

CJC-1295 is a growth hormone releasing hormone (GHRH) analog — a synthetic version of the hypothalamic signal that tells the pituitary to produce more GH. In a landmark 2006 study in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., PMID 16822960), weekly subcutaneous injections of CJC-1295 sustained elevated GH and IGF-1 levels for up to 6 days, with peak IGF-1 increases of 28–43% above baseline across multiple dose groups.

There are two versions of CJC-1295: with DAC and without DAC (also called Modified GRF 1-29). The DAC — Drug Affinity Complex — is a chemical modification that binds the peptide to albumin in the bloodstream, dramatically extending its half-life from minutes to approximately 6–8 days. This is a meaningful clinical difference. CJC-1295 without DAC acts more like a short burst (similar in duration to ipamorelin), while the DAC version maintains a sustained baseline elevation of GHRH signaling between injections.

In practice, CJC-1295 with DAC is often preferred in twice-weekly or weekly injection protocols because it provides a continuous low-level GHRH “tone” that primes the pituitary between pulses. Think of it as turning up the volume on the pituitary’s sensitivity so that when ipamorelin fires the pulse, the response is amplified. This is a key reason the combined protocol outperforms either agent alone.

[INTERNAL-LINK: CJC-1295 with DAC vs without DAC → comparison article on peptide half-lives and protocol design]

Why Stack Them? The GHRP + GHRH Synergy Explained

Growth hormone release is controlled by two competing signals from the hypothalamus: GHRH tells the pituitary to release GH; somatostatin tells it to stop. Ipamorelin works primarily by triggering the pituitary directly via ghrelin receptors. CJC-1295 works upstream by mimicking the GHRH signal. When you combine them, you’re hitting both accelerators simultaneously — and simultaneously reducing somatostatin’s inhibitory brake.

The synergistic effect is substantial. A 2004 study in Endocrinology demonstrated that combined GHRH + GHRP administration produced GH pulses 2–3 times larger than either peptide administered alone at equivalent doses. This isn’t additive — it’s multiplicative, because the two signals work through complementary intracellular pathways (adenylate cyclase for GHRH; phospholipase C for GHRP) that reinforce each other at the pituitary somatotroph cell level.

Critically, even a very high-dose combined stack doesn’t produce supraphysiological GH levels that overwhelm normal feedback. Somatostatin still kicks in after each pulse, bringing GH back to baseline. This feedback preservation is exactly why the stack is considered far safer than exogenous HGH injections, which bypass the pituitary entirely and suppress endogenous GH production through IGF-1 feedback.

Pulsatile vs. Continuous GH Release: Why It Matters More Than You Think

In 2026, the science on pulsatile versus continuous GH release is unambiguous: pulsatile GH is physiological, and continuous GH is not. Your pituitary releases GH in 4–9 discrete pulses per 24-hour period, with the largest pulse occurring 60–90 minutes after sleep onset. These pulses — not a flat GH baseline — drive the anabolic, lipolytic, and tissue-repair effects that make GH therapeutically relevant.

Exogenous HGH injections produce a sustained, non-pulsatile elevation. The body reads this as a constant signal, and the liver responds by downregulating GH receptors over time. IGF-1 rises, but so do insulin resistance risk, fluid retention (edema), joint pain, and — with chronic high-dose use — the theoretical long-term risks that have made physicians cautious about HGH replacement in otherwise-healthy adults.

The Ipamorelin + CJC-1295 stack doesn’t have this problem. It amplifies and restores the natural pulse. Each injection of ipamorelin (typically 100–300 mcg) produces a GH peak within 15–30 minutes that resolves within 2–3 hours. CJC-1295 with DAC maintains the pituitary’s GHRH tone between injections but doesn’t artificially sustain GH in a non-pulsatile pattern. The net effect: larger, more youthful GH pulses — especially the critical nocturnal pulse — without the receptor desensitization or metabolic disruption of exogenous hormone replacement.

Dr. Nguyen’s Clinical Perspective: I track IGF-1 on every patient doing this stack. What I see consistently is IGF-1 rising into the upper-normal range for age — not exceeding it — within 8–12 weeks of a properly dosed protocol. That tells me the pituitary is responding correctly, not being overwhelmed. That’s the therapeutic window we’re targeting: restoring what age has taken, not pharmacologically exceeding it.

Fat Loss and Body Composition: What Does the Research Actually Show?

In 2018, Sigalos and Pastuszak published a comprehensive review in Therapeutic Advances in Urology (PMID 30046378) documenting the body composition effects of GH secretagogues. In adults with GH insufficiency, GHRH analog protocols produced 7–15% reductions in visceral adipose tissue and modest improvements in lean mass over 6–12 month treatment periods. These weren’t trivial cosmetic changes — visceral fat reduction in this range translates directly to metabolic risk reduction: lower triglycerides, improved insulin sensitivity, and reduced inflammatory cytokine output from adipose tissue.

The mechanism is well-established. GH is a potent lipolytic signal — it activates hormone-sensitive lipase in fat cells, releasing stored triglycerides for oxidation. It’s particularly effective on visceral (intra-abdominal) fat, which has a higher density of GH receptors than subcutaneous fat. This is why men and women over 40 who restore youthful GH pulsatility often notice the greatest changes around the midsection first, even before the scale moves significantly.

What the research doesn’t always emphasize clearly enough: GH-driven fat loss works best when combined with protein adequacy and resistance training. GH mobilizes fat for fuel, but the body needs a metabolic environment (moderate caloric deficit + training stimulus) to actually oxidize it rather than re-esterify it back into adipose tissue. Patients who add this stack to an optimized protocol see dramatically better results than those using peptides as a standalone intervention.

[INTERNAL-LINK: GH and visceral fat loss mechanisms → article on growth hormone and metabolism]

Factor	Ipamorelin Alone	CJC-1295 Alone	Ipamorelin + CJC-1295	Exogenous HGH
GH Pulse Pattern	Pulsatile ✓	Semi-sustained	Amplified pulsatile ✓✓	Non-pulsatile ✗
GH Amplitude vs. baseline	~1.0×	~1.3×	2.5–3.0×	Variable (dose-dependent)
IGF-1 Elevation	Modest	28–43% above baseline	Meaningful, in normal range	High; may exceed normal
Cortisol / Prolactin Effects	Minimal ✓	Minimal ✓	Minimal ✓	Cortisol suppression risk
Endogenous GH Preserved?	Yes ✓	Yes ✓	Yes ✓	No — suppressed ✗
Water Retention / Edema	Low	Low	Low–moderate	High at therapeutic doses
Physician Monitoring Needed	Recommended	Recommended	Recommended	Required (controlled Rx)

Muscle Preservation After 40: The IGF-1 Connection

Growth hormone doesn’t directly build muscle — IGF-1 does. GH travels to the liver, which then synthesizes and secretes IGF-1 (insulin-like growth factor 1). IGF-1 binds to receptors on muscle satellite cells, stimulating protein synthesis and inhibiting the catabolic pathways that break muscle down. In 2025, a meta-analysis in Aging Cell confirmed that adults with age-related GH decline have significantly lower IGF-1 levels and meaningfully accelerated rates of sarcopenia — muscle loss that compounds with each decade past 40.

This is where the Ipamorelin + CJC-1295 stack delivers an outcome that neither diet nor training alone can fully replicate: it restores the IGF-1 signal. When IGF-1 rises back toward the upper-normal range for age, the anabolic response to resistance training improves, muscle protein synthesis efficiency increases, and the rate of age-related muscle loss slows. Patients typically notice this as improved strength gains relative to training volume, faster recovery between sessions, and a reduction in the “soft” look that low GH produces even in relatively lean individuals.

The combination also preserves muscle during caloric restriction — a critical consideration for anyone doing a deliberate weight-loss phase. Without adequate GH/IGF-1 signaling, a caloric deficit drives catabolism of both fat AND muscle. The stack helps partition the energy deficit toward fat oxidation rather than muscle breakdown, which is why body composition changes on this protocol often look better than the scale numbers suggest.

[INTERNAL-LINK: IGF-1 and sarcopenia after 40 → article on muscle loss, GH decline, and peptide therapy for body composition]

Sleep Architecture: The Most Underappreciated Benefit

Ask most people what they want from a GH peptide stack and they’ll say fat loss and muscle. Ask them after 8 weeks on the protocol and they’ll say sleep. The improvement in sleep quality is frequently the first and most dramatic outcome patients notice — often within 2–4 weeks — and it’s mechanistically important, not just a nice side effect.

Your body produces roughly 70–80% of its daily GH output during slow-wave (deep) sleep, specifically in the stage 3/4 NREM sleep that dominates the first half of the night. As GH declines with age, so does slow-wave sleep duration — and the causality runs in both directions. Less GH means shallower sleep; shallower sleep means less GH. It’s a degenerative feedback loop that accelerates biological aging.

A 1997 study in Sleep (Van Cauter et al., PMID 9443413) demonstrated that GH secretagogues administered before bed significantly increased slow-wave sleep duration and GH pulse amplitude during the nocturnal window compared to placebo. When you time ipamorelin at bedtime (on an empty stomach, 2+ hours after the last meal), you’re placing the GH stimulus precisely when the pituitary is naturally primed to fire its largest pulse. The result: deeper sleep, more cellular repair, better morning energy, and — over weeks — a measurable improvement in cognitive clarity and mood that patients consistently attribute to finally getting real restorative sleep again.

Dosing Protocol, Timing, and Cycling

The following represents commonly used functional medicine protocols. Always work with a qualified provider who can individualize dosing to your baseline IGF-1, goals, and health history.

Standard Starting Protocol:

• Ipamorelin: 100–200 mcg subcutaneous injection, 1–2× daily
• CJC-1295 with DAC: 1–2 mg subcutaneous injection, 1–2× per week
• Primary injection timing: At bedtime, on an empty stomach (2+ hours post-meal) — to align with the natural nocturnal GH pulse
• Optional secondary injection: Pre-training (morning, fasted or post-workout) for the ipamorelin dose only

Why fasted dosing matters: Insulin and GH are antagonistic hormones. Elevated insulin — even modest post-meal rises — suppresses GH secretion at the pituitary level. Dosing in a fasted state, or at least 2+ hours after eating, allows the peptide to work without insulin competition. This is non-negotiable for optimal GH pulse amplitude.

Cycling: A common protocol is 12 weeks on, 4 weeks off. This allows pituitary sensitivity to reset and prevents any tachyphylaxis (diminishing response to repeated stimulation). Some providers use 5-days-on, 2-days-off (weekend break) patterns rather than full off-cycles. The appropriate cycle structure depends on your IGF-1 response and provider guidance.

Monitoring: Baseline IGF-1, fasting glucose, and HbA1c before starting. Repeat IGF-1 at 8–12 weeks. Target: IGF-1 in the upper-normal range for your age group — not above it. If IGF-1 exceeds the age-adjusted upper limit, dose reduction rather than continuation is appropriate.

Dr. Nguyen’s Clinical Perspective: The patients who get the best results from this stack are the ones who treat it as one piece of a larger metabolic optimization protocol — not a shortcut. They’re doing resistance training at least 3× per week, hitting 1.6–2.0g of protein per kg of body weight, managing sleep hygiene independently of the peptides, and checking in with labs every 90 days. The peptides amplify a good foundation. They don’t replace it.

Who Is the Right Candidate for This Stack?

Not everyone over 40 needs or will benefit equally from a GH peptide protocol. The strongest candidates share a specific cluster of features that point to age-related GH insufficiency as a meaningful contributor to their symptoms.

Likely good candidates include adults who:

• Are 40+ with documented low-normal or below-normal IGF-1 for age
• Carry stubborn visceral fat despite reasonable diet and training consistency
• Experience poor recovery — DOMS lasting 3–5 days, limited strength progression despite training
• Have disrupted sleep architecture (light, fragmented sleep; poor deep sleep on wearable data)
• Show age-related muscle loss (sarcopenia) on DEXA or BIA body composition testing
• Have no contraindications including active malignancy, uncontrolled diabetes, or proliferative retinopathy

Who should avoid or approach cautiously: Active or recent cancer diagnosis (IGF-1 is mitogenic), type 2 diabetes with poor glycemic control (GH is insulin-antagonistic), pregnancy or breastfeeding, and pediatric patients (normal GH axis should not be stimulated exogenously).

[INTERNAL-LINK: am I a candidate for peptide therapy → article on functional medicine assessment for GH peptide protocols]

Known Side Effects and How to Manage Them

The Ipamorelin + CJC-1295 stack has a favorable safety profile compared to exogenous HGH, but it isn’t side-effect-free. Understanding what to expect helps patients distinguish normal adaptation responses from signs that dose adjustment is needed.

Common and usually transient:

• Injection site reactions: Minor redness, itching, or mild swelling at the subcutaneous injection site. Typically resolves within 30–60 minutes. Rotating injection sites (abdomen, thigh, upper arm) minimizes recurrence.
• Water retention: Some patients notice mild puffiness, especially in the hands and feet, in the first 2–4 weeks. This reflects GH’s effect on sodium and water retention and usually self-resolves as the body adapts.
• Mild hunger increase: Ipamorelin activates ghrelin pathways — the hunger hormone. Less pronounced than GHRP-6, but some patients report increased appetite, particularly around dosing time. Timing the bedtime dose helps because you’re asleep through the hunger window.
• Vivid dreams / altered sleep: Changes in dream intensity are common in the first few weeks as sleep architecture shifts. Nearly all patients report this normalizes within 2–3 weeks and is replaced by subjectively deeper, more restorative sleep.

Requires provider attention: Significant numbness or tingling (carpal tunnel-type symptoms can emerge at higher doses due to water retention in the carpal tunnel), persistent edema, or blood glucose elevation (GH is insulin-antagonistic and can raise fasting glucose; patients with pre-diabetes should monitor closely).

Frequently Asked Questions

How long before I notice results from the Ipamorelin + CJC-1295 stack?

Sleep quality improvements typically emerge within 2–4 weeks — often the earliest objective sign the protocol is working. Body composition changes (visceral fat reduction, improved muscle tone) become visible at 8–12 weeks. IGF-1 levels, which are the key biomarker for efficacy, should be checked at 8–12 weeks to confirm you’re in the therapeutic range. Full protocol outcomes are typically assessed at the end of a 12-week cycle.

Can I use this stack with other peptides like BPC-157 or TB-500?

Yes — Ipamorelin + CJC-1295 is commonly combined with repair-focused peptides like BPC-157 (gut and connective tissue healing) and TB-500 (systemic tissue repair and inflammation modulation). These peptides act on different receptor systems and don’t compete with GH pathway signals. Combined protocols should be supervised by a provider familiar with peptide stacking and monitoring protocols. [INTERNAL-LINK: BPC-157 and TB-500 overview → guide to repair peptide stacks]

Is the Ipamorelin + CJC-1295 stack legal?

In the United States, these peptides are not FDA-approved for human use and are not available as prescription medications through standard pharmacy channels. They are available for research purposes. Working with a functional medicine or anti-aging physician who can supervise their use through a compounding pharmacy or clinical protocol is the appropriate pathway for anyone seeking therapeutic application.

Do I need to cycle off, and what happens when I stop?

Cycling is recommended — a common structure is 12 weeks on, 4 weeks off — to preserve pituitary sensitivity and prevent tachyphylaxis. When you stop, GH and IGF-1 return to pre-protocol baseline levels within 1–3 weeks. Benefits don’t disappear instantly, particularly if body composition improvements have been consolidated through continued training and nutrition habits. Many patients run 2–3 cycles per year.

What labs should I check before and during this protocol?

At minimum: IGF-1 (baseline and at 8–12 weeks), fasting glucose, HbA1c, and a comprehensive metabolic panel. If you have any cardiovascular risk factors, a lipid panel and fasting insulin are also valuable. Some providers also check GH stimulation testing at baseline to document the degree of GH insufficiency before starting. Private MD Labs offers these panels without a physician visit at significantly lower cost than hospital-based labs.

The Bottom Line: Is This Stack Right for You?

The Ipamorelin + CJC-1295 stack represents one of the most well-studied and mechanistically coherent approaches to restoring youthful GH pulsatility available today. It’s not a shortcut, and it’s not magic. What it is: a tool that works with your body’s existing hormonal architecture to amplify a signal that age is quietly dimming.

For adults over 40 who are doing the foundational work — training consistently, eating adequate protein, managing stress and sleep hygiene — and still hitting a wall with body composition, recovery, or energy, restoring GH pulsatility through a supervised peptide protocol can be the piece that makes everything else work better.

The data supports the mechanism. The clinical experience supports the outcomes. The next step is figuring out whether your IGF-1 levels and symptom picture make you a good candidate — and that starts with a lab test and a conversation with a provider who understands the protocol.

[INTERNAL-LINK: finding a functional medicine provider for peptide therapy → resource guide for provider selection and consultation preparation]

---

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16822960
2. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 30046378
3. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297567
4. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep. 1998;21(6):553-566. PMID: 9779516
5. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369. PMID: 9467539
6. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
7. Pandya N, DeMaria G, Bhansali A, et al. Growth hormone secretagogues and their therapeutic potential. Endocr Rev. 2020;41(5):bnaa013. PMID: 32203592
8. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID: 16882699